abstract |
Disclosed is a sustained release dosage form, comprising an osmotic dosage form, a matrix dosage form, or a coated bead dosage form, comprising a substituted pyrazine derivative wherein the dosage form is effective to provide sustained release for at least about 8 hours, and wherein the dosage form is effective to provide a plasma profile at steady state wherein Cmax/Cmin is less than or equal to 3. Also disclosed is the use of the dosage form for treating a central nervous system such as epilepsy, or for treating psychiatric disorders. |